Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Disease-Modifying Therapy in Multiple Sclerosis: Mechanism of Action, Risks, and Benefits

neuroscienceCME Webcast

Premiere Date: Friday, January 8, 2016

This activity offers CE credit for:

1. Physicians (CME)
2. Pharmacists (ACPE)
3. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Sunday, January 8, 2017
Note: Credit Is No Longer Available

Faculty

Michael K. Racke, MD  Neurology Medical Director Quest Diagnostics Secaucus, NJ

Patricia K. Coyle, MD, FAAN, FANA  Professor and Vice Chair (Clinical Affairs) Department of Neurology Director, MS Comprehensive Care Center Stony Brook University Medical Center Stony Brook, NY

Brant J. Oliver, PhD, MS, MPH, APRN-BC  Assistant Professor, School of Nursing MHG Institute of Health Professions Boston, MA Adjunct Assistant Professor Dartmouth Institute of Health Policy & Clinical Practice Geisel School of Medicine Dartmouth College Hanover, NH VT Neurobehavioral Specialists Multiple Sclerosis Specialty Care Program Concord Hospital Concord, NH

Statement of Need

Multiple sclerosis (MS) strikes people in the prime of their lives, affecting upwards of 400,000 people in the United States and 2.5 million worldwide.¹ However, a diagnosis of MS is no longer a sentence of doom; “the MS landscape has been comprehensively and irreversibly transformed by progress”² in understanding the pathophysiology of the disease and the development of targeted therapy. As new therapeutic options become available, establishing effective patient-centric treatment plans, based upon newly identified targets and incorporating mechanism of action, will be increasingly essential to achieving optimum quality of life for all of these individuals.

On December 9, 2015, a neuroscienceCME Live and On Demand featured a discussion of pathophysiology of the multiple sclerosis and the development of targeted therapy. To meet the learning preferences of busy clinicians, the activity has been divided into three short modules.

Module 1: Disease-Modifying Therapy in Multiple Sclerosis: Mechanism of Action, Risks, and Benefits Click here to begin this activity now

Module 2: Using Shared Decision Making to Determine Factors That Matter to Your Patients With Multiple Sclerosis Click here to access this activity

Module 3: Understanding and Explaining Risk and Point of Care Decision Tools for Multiple Sclerosis Click here to access this activity

Each module is certified for .5 AMA PRA Category 1 Credit™. We encourage participants to complete all three modules to optimize the learning experience and to gain valuable insights for treating their patients with multiple sclerosis.

---

1. Dubey D, Kieseier BC, Hartung HP, Hemmer B, Miller-Little WA, Stuve O. Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates. Expert Rev Clin Immunol. 2015;11(1):93-108. PMID: 25495182.
2. Du Pasquier RA, Pinschewer DD, Merkler D. Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis. CNS Drugs. 2014;28(6):535-558. PMID: 24723124.

Learning Objectives

At the end of this CE activity, participants should be able to:

• When selecting disease-modifying therapy for a specific patient, include the mechanism of action of each agent and its safety profile into the decision-making process.

Financial Support

Supported by educational grants from Genzyme, a Sanofi Company and Novartis Pharmaceuticals Corporation.

Target Audience

Neurologists, general practitioners, NP, PA, pharmacists and other health care professionals interested in multiple sclerosis.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs)
Universal Activity Number: 0376-0000-16-016-H01-P
Activity Type: knowledge-based

Successful completion of this CE activity includes participating in the live or recorded activity, reviewing the course materials, and following the appropriate set of instructions below within 30 days of completion of the activity:

To complete your activity evaluation and post-test online, and print your certificate or statement of credit immediately (75% pass rate required), please visit http://www.cmeoutfitters.com/transfers/tst/?ID=20073 (requires free account activation).

There is no fee for participation in this activity. The estimated time for completion is 90 minutes.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Racke has disclosed that he has received grant/research support from National Institutes of Health; National Multiple Sclerosis Society; Novartis Corporation; and Roche (pharma support is for clinical trials). He serves as a consultant to EMD Serono, Inc.; Roche/Genentech, Inc.; and Novartis Corporation.

Dr. Coyle has disclosed that she has received grant/research support from Actelion Pharmaceuticals US, Inc.; Biogen Idec, Inc.; Genentech, Inc./Roche; Novartis; and Opexa Therapeutics, Inc. She serves as a consultant to AbbVie Inc.; Accordant; Acorda Therapeutics; Biogen; Genentech, Inc./Roche; Genzyme Corporation/sanofi-aventis U.S. LLC; Novartis; EMD Serono, Inc.; and Teva Pharmaceuticals USA

Dr. Oliver has disclosed that he has received grant/research support from Teva Neuroscience, Inc.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.

Catherine Murray (planning committee) has no disclosures to report.

Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.

Disclosures have been obtained from CME Outfitters staff: No disclosures to report.

Unlabeled Use Disclosure

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

CME Outfitters, LLC, the faculty, Genzyme, a Sanofi Company and Novartis Pharmaceuticals Corporation do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).